Get the Stockscreener App
0.8203
0.00%
0.00
After Hours:
.82
-0.0003
-0.04%
Cue Biopharma Inc stock is traded at $0.8203, with a volume of 147.27K.
It is up +0.00% in the last 24 hours and up +10.70% over the past month.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
See More
Previous Close:
$0.8203
Open:
$0.8162
24h Volume:
147.27K
Relative Volume:
0.48
Market Cap:
$61.81M
Revenue:
$9.53M
Net Income/Loss:
$-44.61M
P/E Ratio:
-0.9014
EPS:
-0.91
Net Cash Flow:
$-38.32M
1W Performance:
-8.75%
1M Performance:
+10.70%
6M Performance:
-38.78%
1Y Performance:
+26.82%
1-Day Range:
$0.805
$0.84
1-Week Range:
$0.805
$0.92
52-Week Range:
$0.45
$1.9891
Cue Biopharma Inc Stock (CUE) Company Profile
Name
Cue Biopharma Inc
Sector
Industry
Phone
617-949-2680
Address
40 GUEST STREET, BOSTON, MA
Compare CUE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CUE
Cue Biopharma Inc
|
0.8203 | 61.81M | 9.53M | -44.61M | -38.32M | -0.91 |
|
VRTX
Vertex Pharmaceuticals Inc
|
468.41 | 118.34B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.14 | 60.31B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
330.55 | 42.35B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
598.79 | 36.43B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
305.74 | 31.87B | 3.81B | -644.79M | -669.77M | -6.24 |
Cue Biopharma Inc Stock (CUE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-13-24 | Initiated | Jefferies | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Nov-21-22 | Initiated | Piper Sandler | Overweight |
| Jan-13-22 | Initiated | H.C. Wainwright | Buy |
| Jan-03-22 | Initiated | Craig Hallum | Buy |
| Nov-24-20 | Initiated | Berenberg | Buy |
| Apr-09-20 | Initiated | Stifel | Buy |
| Jan-28-20 | Initiated | BTIG Research | Buy |
| Jan-22-20 | Initiated | JMP Securities | Mkt Outperform |
View All
Cue Biopharma Inc Stock (CUE) Latest News
What makes Cue Biopharma Inc. stock price move sharplyLoss Limitation Strategy Based on Analysis - Newser
How Cue Biopharma Inc. stock performs during market volatilityTrade Safety Matrix for Conservative Traders - Newser
Will Cue Biopharma Inc. stock benefit from interest rate changesBreakout Confirmation With Entry Tracker Enabled - metal.it
Why Cue Biopharma Inc. stock attracts strong analyst attentionFree Risk Adjusted Technical Entry Plan - Newser
Why Cue Biopharma Inc. stock is on top investor watchlistsWeekly Stock Picks with Trend Confidence - Newser
Can machine learning forecast Cue Biopharma Inc. recoveryFree Weekly Setup With 3x Return Potential - Newser
Buy Signal for Cue Biopharma Inc. Stock Key Technical Indicators to WatchEarnings Impact and Stock Reaction Analysis - Newser
How did CUE's Q4 earnings surprise impact investor confidence? - AInvest
Using data models to predict Cue Biopharma Inc. stock movementEntry Timing Tracker with Alert Accuracy - Newser
What technical models suggest about Cue Biopharma Inc.’s comebackMarket Opportunity Tracker for Swing Traders - Newser
Published on: 2025-07-28 23:49:57 - metal.it
Cue Biopharma Inc. Flashes Buy Signal on Multi Timeframe ChartCommunity Strategy With High Win Rate Backtested - metal.it
What are analysts’ price targets for Cue Biopharma Inc. in the next 12 monthsExplosive market performance - jammulinksnews.com
What are the latest earnings results for Cue Biopharma Inc.Stay ahead with advanced stock screening tools - jammulinksnews.com
Earnings visualization tools for Cue Biopharma Inc.Weekly Gain Forecast with Momentum Indicators - Newser
How does Cue Biopharma Inc. compare to its industry peersUnlock expert trading strategies for growth - jammulinksnews.com
Using AI based signals to follow Cue Biopharma Inc.Weekly Signal Report with Trend Summary - Newser
What catalysts could drive Cue Biopharma Inc. stock higher in 2025Breakthrough capital growth - jammulinksnews.com
Is Cue Biopharma Inc. stock overvalued or undervaluedGet high-impact stock recommendations now - jammulinksnews.com
Cue Biopharma Inc. Stock Support and Resistance Levels You Should KnowOptimized Return Investment Picks - Newser
Intrinsic Value of Cue Biopharma Inc. Stock: Is It Undervalued or OvervaluedSafety First Trading Signals - Newser
why cue biopharma inc. stock attracts strong analyst attentionCapital Doubling Tips - Newser
Will Cue Biopharma Inc. stock split in the near futureConsistently high yield - jammulinksnews.com
What analysts say about Cue Biopharma Inc. stockConsistently outstanding ROI - PrintWeekIndia
What analysts say about Cue Biopharma Inc. stock outlookFree Consultation - jammulinksnews.com
What drives Cue Biopharma Inc. stock priceFree High-Return Strategy Alerts - Autocar Professional
Pancreatic Cancer Market to Show Remarkable Growth Trends from - openPR.com
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
Is Cue Biopharma Inc. a good long term investmentBreakthrough profits - jammulinksnews.com
Cue Biopharma Inc. Stock Analysis and ForecastPhenomenal investment performance - jammulinksnews.com
Cue Biopharma Inc Stock (CUE) Financials Data
Revenue
Net Income
Cash Flow
EPS
10.28%
2.59%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):